Paroxysmal ventricular fibrillation (PVF) is one of the most dangerous types of arrhythmia, characterized by chaotic and ineffective electrical activity of the ventricles of the heart. This condition can lead to cardiac arrest and, as a consequence, to sudden cardiovascular death. PVF most often occurs against the background of ischemic heart disease, and can also be provoked by other factors, such as electrolyte disturbances, toxic effects, heart trauma and various cardiomyopathies. The pathophysiology of this condition includes disturbances in conduction and automaticity of the heart muscle, which leads to uncoordinated contractile activity with the absence of effective ejection of blood into the systemic circulation. The temporal aspect of the occurrence of PVF, its paroxysmal nature, as well as the need for immediate intervention make this condition extremely relevant in cardiology.
History of the disease and interesting historical facts
Paroxysmal ventricular fibrillation was first described in the early 20th century, although there were a number of observations of cardiac fibrillation even earlier. In the 1930s, with the development of electrocardiography (ECG), scientists were able to study the electrical activity of the heart in more detail. One of the first steps in understanding the mechanism of fibrillation was the discovery that the disease can be caused by triggering events, which was confirmed in a series of clinical studies in the 1950s and 1960s. In the 1980s, active research began to study the genetic aspects, which gave rise to new approaches in cardiology and echocardiography. An interesting milestone in the history of PVF was the introduction of electrical shock as a method of restoring the heart rhythm, which was introduced into practice in the 1970s and remains the standard in emergency care.
Epidemiology
Paroxysmal ventricular fibrillation is one of the most common arrhythmias observed in clinical practice. According to various studies, its incidence varies from 1 to 4% in the general population, depending on the age group and the risk factors present. In patients with coronary artery disease and progressive heart failure, the incidence of PVF increases significantly, reaching 10-20%. Gender differences in incidence have also been noted: men suffer from PVF more often than women, which may be due to differences in risk factors and pathophysiology of cardiovascular diseases. It is important to note that given the aging of the population and the increase in the lifespan of the elderly, the incidence of PVF is expected to increase in the future.
Genetic predisposition to this disease
Undoubtedly, genetic predisposition plays an important role in the development of paroxysmal ventricular fibrillation. Studies have shown that various genetic mutations may be associated with an increased risk of developing arrhythmia. The main genes involved are those encoding ion channels and are responsible for the electrical activity of the myocardium. For example, mutations in the SCN5A, KCNQ1, and KCNH2 genes may be associated with hereditary forms of arrhythmia. These genes are responsible for the function of sodium and potassium channels involved in the depolarization and repolarization of cardiomyocytes. Additional studies reveal relationships between polymorphisms in these genes and clinical manifestations of PVF, emphasizing the importance of genetic testing in patients with a family history of cardiac arrhythmias.
Risk factors for the development of this disease
There are many risk factors that contribute to the development of paroxysmal ventricular fibrillation. The main ones include:
- Ischemic heart disease
- Aging and associated cardiovascular diseases
- Hypertension and heart failure
- Electrolyte disturbances (eg, hypokalemia, hypomagnesemia)
- Alcohol and drug abuse
- Toxic exposure (eg chemicals, drugs)
- Physical stress and emotional overload
- Certain thyroid diseases (hyperthyroidism)
- Hereditary factors and predisposition to arrhythmia
Understanding these risk factors may aid in the prevention and early diagnosis of PFG, which is especially important for high-risk patients.
Diagnosis of this disease
Diagnosis of paroxysmal ventricular fibrillation includes several stages. The main symptoms that may indicate the development of PVF include:
- Sudden onset of rapid heartbeat
- Dizziness and fainting
- Chest pain
- Dyspnea
- Loss of consciousness
Laboratory tests may include blood tests to assess electrolyte balance, as well as tests for stress and hypoxia. Radiological tests, such as echocardiography, help evaluate the structure of the heart and identify possible causes of PFV. Many experts recommend the use of long-term ECG monitoring (Holter) to record arrhythmias over a longer period of time. Differential diagnosis includes ruling out other causes of symptoms: myocardial infarction, pulmonary embolism, and other potentially life-threatening conditions.
Treatment
Treatment of paroxysmal ventricular fibrillation should be aimed at restoring an effective heart rhythm and preventing possible complications. Depending on the clinical situation, the following approaches can be used:
- General treatment, including the use of electrical cardioversion in emergency situations
- Pharmacological treatment, including antiarrhythmic drugs such as amiodarone, flecainide, or sotalol
- Surgical procedures such as ablation or implantable cardioverter defibrillator (ICD)
- Other treatments, such as using beta blockers to control heart rhythm
The decision on the method of treatment is made individually, taking into account the cause of the PFG and the patient's condition.
List of medications used to treat this disease
Pharmacological treatment of paroxysmal ventricular fibrillation involves the use of various classes of drugs. The main medications include:
- Amiodarone
- Flecainide
- Sotalol
- Disopyramide
- Beta blockers (eg, metoprolol, propranolol)
- Anticoagulants to prevent thrombus formation (eg, rivaroxaban, apixaban)
These drugs help manage arrhythmia and prevent serious complications.
Disease monitoring
Monitoring of patients with paroxysmal ventricular fibrillation is an important part of the management of this disease. Monitoring includes the following steps:
- Regular check-ups with a cardiologist
- ECG monitoring to detect recurrent arrhythmia
- Assessment of thrombotic risk and hemodynamic characteristics
- Psychological support and recommendations for lifestyle changes
The prognosis with timely and adequate treatment is favorable, but the risk of complications such as sudden cardiac death remains high. It is important to respond promptly to deterioration of the condition and control risk factors.
Age-related features of the disease
Paroxysmal ventricular fibrillation may present differently depending on the age group. In older patients, it is more often associated with comorbid conditions such as heart failure, ischemic heart disease, and hypertension. In younger people, on the contrary, PVF may be associated with hereditary forms of arrhythmia or substance abuse. Of course, age differences also affect treatment approaches: in older patients, many comorbidities and drug interactions must be taken into account, while in younger people, the emphasis may be on more aggressive methods such as ablation.
Questions and Answers
- What is paroxysmal ventricular fibrillation? This is a condition characterized by abnormal electrical activity of the ventricles of the heart, which can lead to cardiac arrest and requires emergency medical care.
- What are the main causes of PFG? Common causes include coronary heart disease, electrolyte disturbances, and alcohol abuse.
- How is PFG diagnosed? Diagnosis includes assessment of symptoms, laboratory and radiological studies, and ECG monitoring.
- What is the treatment for PFG? Treatment may be pharmacological, surgical, and include electrical cardioversion in emergency cases.
- What is the prognosis for patients with PFG? The prognosis depends on the cause and severity, but with adequate treatment, most patients have a favorable outcome.
